drugset / Trial / NCT00134875

Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers

NCT00134875

RandomizedParallel-groupDouble-blindTreatment

Summary

Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal symptoms in opioid dependent individuals. However, naloxone does not cause withdrawal symptoms in non-dependent opioid abusers. This study will investigate whether naloxone decreases the opioid agonist effect from injected buprenorphine, hence decreasing the abuse potential of buprenorphine/naloxone, in non-dependent opioid abusers.

Timeline

Start
2000-12
Primary completion
2002-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 4 mg Other
Subject Buprenorphine Other / unclassified 8 mg Other
Subject Buprenorphine Other / unclassified 16 mg Other
Subject Naloxone Small molecule 1 mg Other
Subject Naloxone Small molecule 2 mg Other
Subject Naloxone Small molecule 4 mg Other